title: Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.
authors.forename: M G
authors.initials: MG
authors.lastname: Kris
authors.forename: J E
authors.initials: JE
authors.lastname: Radford
authors.forename: B A
authors.initials: BA
authors.lastname: Pizzo
authors.forename: R
authors.initials: R
authors.lastname: Inabinet
authors.forename: A
authors.initials: A
authors.lastname: Hesketh
authors.forename: P J
authors.initials: PJ
authors.lastname: Hesketh
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D002945:Cisplatin; C099414:(2S,3S)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine